William Blair Has Negative Estimate for DVAX FY2025 Earnings

Dynavax Technologies Co. (NASDAQ:DVAX) – William Blair cut their FY2025 earnings per share (EPS) estimates for Dynavax Technologies in a report issued on Wednesday, May 7th. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings per share of $0.25 for the year, down from their prior estimate of $0.28. William Blair has a “Outperform” rating on the stock. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.32 per share.

Other research analysts have also recently issued reports about the company. JMP Securities decreased their price objective on Dynavax Technologies from $33.00 to $31.00 and set a “market outperform” rating on the stock in a report on Wednesday. HC Wainwright reissued a “buy” rating and set a $31.00 price objective on shares of Dynavax Technologies in a research report on Friday, February 21st. The Goldman Sachs Group decreased their target price on shares of Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating on the stock in a research report on Thursday, April 17th. Finally, StockNews.com downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $24.00.

Dynavax Technologies Price Performance

Shares of DVAX stock opened at $9.41 on Friday. The firm’s 50-day moving average is $12.24 and its two-hundred day moving average is $12.55. Dynavax Technologies has a 12 month low of $9.28 and a 12 month high of $14.63. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The company has a market capitalization of $1.15 billion, a PE ratio of 52.28 and a beta of 1.26.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.14). Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The company had revenue of $68.16 million for the quarter, compared to analysts’ expectations of $70.01 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. raised its holdings in Dynavax Technologies by 96.5% in the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 1,169 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in shares of Dynavax Technologies during the 1st quarter worth $30,000. Smartleaf Asset Management LLC grew its stake in shares of Dynavax Technologies by 463.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 2,034 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Dynavax Technologies in the fourth quarter valued at $35,000. Finally, GAMMA Investing LLC lifted its holdings in Dynavax Technologies by 55.1% during the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after buying an additional 1,457 shares during the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.